Evidence map›Paper›PMID 29399722›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Rural versus urban differences in end-of-life care for lung cancer patients in Germany.

Julia Walter, Amanda Tufman, Reiner Leidl, Rolf Holle, Larissa Schwarzkopf

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. End-of-Life Cancer Care Resource Utilisation in Rural Versus Urban Settings: A Systematic Review.International journal of environmental research and public health · 2020
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Scoping review of anticancer drug utilization in lung cancer patients at the end of life.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  6. Frequency of anticancer drug use at the end of life: a scoping review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Julia WalterGerman Research Center for Environmental Health, Helmholtz Zentrum München, Institute for Health Economics and Health Care Management (IGM), Ingolstädter Landstraße 1, 85764, Neuherberg, Germany. julia.walter@helmholtz-muenchen.de.ORCID http://orcid.org/0000-0003-4304-6159
Amanda TufmanGerman Center for Lung Research (DZL), Aulweg 130, 35392, Gießen, Germany.
Reiner LeidlGerman Research Center for Environmental Health, Helmholtz Zentrum München, Institute for Health Economics and Health Care Management (IGM), Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Rolf HolleGerman Research Center for Environmental Health, Helmholtz Zentrum München, Institute for Health Economics and Health Care Management (IGM), Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Larissa SchwarzkopfGerman Research Center for Environmental Health, Helmholtz Zentrum München, Institute for Health Economics and Health Care Management (IGM), Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Helmholtz Zentrum München · DEGerman Center for Lung Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess rural-urban differences in healthcare utilization and supportive care at the end-of-life in German lung cancer patients.

methodsWe identified 12,929 patients with incident lung cancer in 2009 from claims data and categorized them to four district types (major city, urban, rural, remote rural). We compared site of death, unplanned hospitalizations, hospital days, outpatient doctor, general practitioner (GP) and home visits, structured palliative care, therapy with antidepressants, pain relief medication and chemotherapy, and therapeutic puncturing in the last 30 and 14 days of life using mixed models with logistic link function for binary outcomes and log link function for count data. We adjusted all models by age, sex, comorbidities, metastases location and presence of multiple tumors at diagnosis, survival in months, and type of tumor-directed treatment.

resultsWe found significant differences in two of the outcomes measured. The likelihood of > 14 hospital days in the last 30 days was significantly higher in rural districts than in remote rural districts (1.27 [1.05, 1.52], p = 0.0003). The number of visits to the GP in the last 30 days of life was significantly lower in urban districts than in remote rural districts (β = - 0.19 [- 0.32, - 0.06], p = <0.0001). No other endpoints were associated with regional differences. Triggering factors for high and low utilization of healthcare were mostly age, comorbidities, and prior anticancer treatment.

conclusionHealthcare utilization and supportive care did not differ significantly between different district types. Results reject the hypothesis of regional inequity in end-of-life care of lung cancer patients in Germany.

Indexed as

AgedFemaleGermanyHumansLung NeoplasmsMalePalliative CareRetrospective StudiesRural PopulationTerminal CareUrban PopulationClaims dataDeathEqualityQuality of careRegional differencesRurality

Identifiers

PMID29399722
OpenAlexW2793378970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.